A Phase 3, Controlled, Open-label, Randomized Study of RRx-001 Administered Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Lung Cancer
Phase of Trial: Phase III
Latest Information Update: 22 Nov 2019
Price : $35 *
At a glance
- Drugs RRx 001 (Primary) ; Carboplatin; Cisplatin; Etoposide
- Indications Carcinoma; Small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms REPLATINUM
- Sponsors EpicentRx
- 13 Nov 2019 According to an EpicentRx media release, funding from the recent financing round, enables the company to advance clinical development of our lead cancer programs, including this phase III trial.
- 05 Nov 2019 According to a EpicentRx media release, first patient has been dosed in this study.
- 14 Aug 2019 Planned number of patients changed from 120 to 126.